Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort
Alexander Egeberg, Kyoungah See, Alyssa Garrelts, et al.
BMC Dermatology (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort
Alexander Egeberg, Y.M.F. Andersen, Jacob P. Thyssen
BMJ Open (2019) Vol. 9, Iss. 3, pp. e028116-e028116
Open Access | Times Cited: 77
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
Marco Galluzzo, Mark S. Talamonti, Arnaldo Cioni, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2631-2631
Open Access | Times Cited: 49
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)
Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 20
Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial
Sascha Gerdes, Beate Bräu, Matthias Hoffmann, et al.
The Journal of Dermatology (2021) Vol. 48, Iss. 12, pp. 1854-1862
Open Access | Times Cited: 37
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Linda Stein Gold, Kim Papp, David M. Pariser, et al.
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 1, pp. 77-85
Closed Access | Times Cited: 34
Challenge of Nail Psoriasis: An Update Review
Chao Ji, Haiqing Wang, Chengbei Bao, et al.
Clinical Reviews in Allergy & Immunology (2021) Vol. 61, Iss. 3, pp. 377-402
Closed Access | Times Cited: 33
Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey
April W. Armstrong, Barbra Bohannan, S. Mburu, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 4, pp. 1055-1064
Open Access | Times Cited: 25
Autoantibodies - enemies, and/or potential allies?
Hui Ma, Caroline Murphy, Christine E. Loscher, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
Alin Codruț Nicolescu, M Ionescu, M. Constantin, et al.
Life (2022) Vol. 12, Iss. 12, pp. 2050-2050
Open Access | Times Cited: 25
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States
Joseph F. Merola, Haijun Tian, Dhaval Patil, et al.
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 4, pp. 748-757
Open Access | Times Cited: 30
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
Leon Kircik, Javier Alonso‐Llamazares, Neal Bhatia, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 4, pp. 392-399
Open Access | Times Cited: 13
Association between the severity of hard-to-treat psoriasis and the prevalence of metabolic syndrome: A hospital-based cross-sectional study in Jakarta, Indonesia
Dina Evyana, Endi Novianto, Windy Keumala Budianti, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0302391-e0302391
Open Access | Times Cited: 4
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study
Federico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Dermatology and Therapy (2025)
Open Access
The effectiveness of using a combination of glucocorticosteroid and salicylic acid in the form of a solution for psoriasis vulgaris of the scalp
Antonina A. Arsenieva, Е. В. Орлов, J. M. Pakhomova
Meditsinskiy sovet = Medical Council (2025), Iss. 23, pp. 199-204
Open Access
PSO-TARGET: a New Tool to Identify the Therapeutic Expectations of Psoriasis Patients Treated with Biologics
Z. Reguiaï, Pierre-Dominique Ghislain, Pierre Moulin, et al.
Dermatology and Therapy (2025)
Open Access
Nail Psoriasis
Eden Axler, Shari R. Lipner
(2025), pp. 55-61
Closed Access
Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life
Matthias Augustin, Juliet N. Barker, Curdin Conrad, et al.
Dermatology and Therapy (2025)
Open Access
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
Melinda Gooderham, Javier Alonso‐Llamazares, Jerry Bagel, et al.
JAMA Dermatology (2025)
Closed Access
Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life
Dorota Purzycka-Bohdan, Anna Kisielnicka, Monika Zabłotna, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 5, pp. 1254-1254
Open Access | Times Cited: 15
Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab
Sascha Gerdes, K. Asadullah, Matthias Hoffmann, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 9, pp. 1568-1577
Open Access | Times Cited: 15
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study
Kurt Gebauer, Lynda Spelman, Paul S. Yamauchi, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 1, pp. 91-99
Open Access | Times Cited: 3
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
Alan Menter, Tina Bhutani, Benjamin D. Ehst, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1289-1302
Open Access | Times Cited: 14
Extracellular matrix alterations in the skin of patients affected by psoriasis
Mariana Fatima Muaccad Gama Wagner, Thérèse Rachell Theodoro, Carlos D’. Apparecida Santos Machad Filho, et al.
BMC Molecular and Cell Biology (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China
Jing Yang, Kun Hu, Xingyu Li, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 443-451
Open Access | Times Cited: 7
Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G‐EPOSS study
Sascha Gerdes, Rolf Ostendorf, Anke Süß, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top